RecruitingPhase 3NCT07011732
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Sponsor: Bristol-Myers Squibb
Middletown, NJ · Princeton, NJ · +39 more sites